NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study on Long-Term Efficacy and Safety of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (FAct)

NCT01483326

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Rheumatoid Arthritis

Countries: Netherlands

This observational study will evaluate the long-term efficacy and safety of RoActemra/Actemra (tocilizumab in participants of the ACT SURE clinical trial and further patients with moderate to severe rheumatoid arthritis starting or receiving RoActemra/Actemra. Data will be collected from each patient for up to 4 years.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Adult patients, \>18 years of age
* Participants in the ACT-SURE trial, or patients with moderate to severe rheumatoid arthritis starting or receiving RoActemra/Actemra

Exclusion Criteria:

* Contra-indications for RoActemra/Actemra

Locations (19)

Amsterdam, Netherlands
Apeldoorn, Netherlands
Arnhem, Netherlands
Breda, Netherlands
Deventer, Netherlands
Emmeloord, Netherlands
Emmen, Netherlands
Enschede, Netherlands
Flushing, Netherlands
Gouda, Netherlands
Hardenberg, Netherlands
Hilversum, Netherlands
Leeuwarden, Netherlands
Maastricht, Netherlands
Nieuwegein, Netherlands
Nijmegen, Netherlands
Rotterdam, Netherlands
Schiedam, Netherlands
The Hague, Netherlands